Drug intelligence / Profile preview

[68Ga]Ga-ELI421

Development stage: Phase 2
Lead developer: Union Hospital of Huazhong University of Science and Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

[68Ga]Ga-ELI421 is a radiopharmaceutical diagnostic agent developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. It is a PET imaging tracer designed to target Prostate-Specific Membrane Antigen (PSMA) for the detection and staging of prostate cancer. The agent utilizes the positron-emitting isotope Gallium-68 (68Ga) conjugated to the ELI421 ligand. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety, biodistribution, radiation dosimetry, and diagnostic efficacy in patients with prostate cancer.

Other names: [68Ga]Ga-ELI421 injection

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on [68Ga]Ga-ELI421.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-ELI421.

Explore the full profile